Inventiva S.A. (IVA.PA) Stock
Inventiva S.A. is a biopharmaceutical firm currently in the clinical development phase, specializing in creating orally administered small molecule treatments for conditions such as non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and various other ailments.
Valuation
Financials & Margins
Latest News
Valuation & Return Ratios
Peer Comparison
About Inventiva S.A.
Inventiva S.A. is a biopharmaceutical firm currently in the clinical development phase, specializing in creating orally administered small molecule treatments for conditions such as non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and various other ailments. Their primary drug candidate, Lanifibranor, has successfully concluded Phase IIb clinical trials for the management of NASH. Furthermore, the company is advancing Odiparcil, a compound that has finished Phase IIa clinical testing specifically for treating the MPS VI subtype. Beyond these, Inventiva maintains a development pipeline featuring several early-stage projects targeting oncology and other medical conditions. Strategic partnerships are in place with AbbVie to address autoimmune diseases, and with Boehringer Ingelheim International GmbH for innovating therapies for idiopathic pulmonary fibrosis. Established in 2011, Inventiva S.A. operates from its headquarters in Daix, France.
Inventiva S.A. is led by CEO Andrew Obenshain, employs 73 people, headquartered in Daix, FR, publicly traded since 2017.
over the past 52 weeks the stock has ranged between $2.88 and $6.20, and currently trades 34.0% below its 52-week high.
Official website: www.inventivapharma.com